Fed policy and broader market trends are likely to continue influencing investment decisions in the weeks ahead
Anticipation for a Federal Reserve interest rate cut in June has tempered, with the probability of at least a 25 basis point reduction standing at 59.1%, a decline from the near certainty seen at the close of January, as indicated by the CME Group's FedWatch tool.
This week, market observers are closely monitoring several key economic indicators that could shape expectations surrounding Fed policy. Among the data expected are the second estimate of gross domestic product, jobless claims figures, and updates on manufacturing activity.
Recent economic reports have reflected a mixed picture. U.S. consumer confidence saw a retreat in February following a three-month uptrend, while January witnessed orders for long-lasting U.S. manufactured goods falling more than anticipated.
Amidst these developments, market sentiment received a boost from Apple, which rebounded late in the session to close up 0.81%, reportedly shifting focus from its electric car project to its artificial intelligence endeavors. Conversely, UnitedHealth experienced a late dip, closing down 2.27%, following reports of an antitrust investigation initiated by the U.S. Department of Justice.
In the pharmaceutical sector, Viking Therapeutics saw a remarkable surge of 121.02% after reporting positive results from its mid-stage study of an experimental obesity treatment. Conversely, Amgen, a competitor in the weight-loss drug space, experienced a decline of 2.75%.
As market participants analyze incoming economic data and corporate developments, shifts in sentiment regarding Fed policy and broader market trends are likely to continue influencing investment decisions in the weeks ahead.
